Interim Safety of RSVpreF Vaccination During Pregnancy

JAMA 2026 Open access

Read full text
Authors: Ashley I. Michnick, Sarah C. MacDonald, Austin Cosgrove, Sruthi Adimadhyam, Fang Zhang, Andrew B. Petrone, Katherine E. Round, Sampada Gandhi, Nana Koram, Olympia E. Anastasiou, Heather Rubino, Maria Maddalena Lino
+9 more Djeneba Audrey Djibo, Kuntz Jl, S B Love, Cheryl N. McMahill‐Walraven, Kristin Palmsten, Anna E. Wentz, Judith C. Maro, Richard Platt, Susan E. Andrade
DOI: 10.1001/jama.2025.23452
Cited by: 7
References: 3

Abstract

This interim analysis of an ongoing retrospective cohort study uses data from 5 US health plans to assess safety of a bivalent prefusion F subunit–based respiratory syncytial virus (RSV) vaccine administered during pregnancy during the first full RSV season after US Food and Drug Administration approval (from September 22, 2023, through June 14, 2024).

Fields of Study & Subjects

Respiratory viral infections research COVID-19 Impact on Reproduction Parvovirus B19 Infection Studies

Publication details

Journal / source
JAMA
Publisher
American Medical Association (AMA)
Volume
335
Issue
5
Pages
456–456
Publication date
8 January 2026
Language
EN